NCT00179309View on ClinicalTrials.gov

Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

February 28, 2013

Study Completion Date

October 31, 2013

Conditions
Breast Cancer
Interventions
DRUG

Docetaxel

35 mg/m\^2 intravenous 30-60 minutes once a week for 3 consecutive weeks with 1 week off drug.

BIOLOGICAL

PANVAC-V

2 x 10\^8 PFU

BIOLOGICAL

PANVAC-F

1 x 10\^9 PFU

BIOLOGICAL

Sargramostim

Given subcutaneously under the skin, usually in the thigh on the day of vaccination and daily for the next 3 days.

Trial Locations (2)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

77030-4096

U.T.M.D. Anderson Cancer Center, Houston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00179309 - Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer | Biotech Hunter | Biotech Hunter